<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To determine the maximum tolerated dose and describe the toxicities of 9-cis-<z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (9cRA, ALRT1057) administered p.o. tid in pediatric patients with <z:e sem="disease" ids="C0677936" disease_type="Neoplastic Process" abbrv="">refractory cancer</z:e> and to study the pharmacokinetics of 9cRA and determine whether systemic drug exposure changes with <z:hpo ids='HP_0011010'>chronic</z:hpo> dosing </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Children with <z:e sem="disease" ids="C0677936" disease_type="Neoplastic Process" abbrv="">refractory cancer</z:e> (stratified by age, &lt; or =12 and &gt;12 years) were treated with p.o </plain></SENT>
<SENT sid="2" pm="."><plain>9cRA for 28 consecutive days </plain></SENT>
<SENT sid="3" pm="."><plain>The starting dose was 50 mg/m(2)/day divided into 3 doses with planned escalations to 65, 85, and 110 mg/m(2)/day </plain></SENT>
<SENT sid="4" pm="."><plain>Pharmacokinetic sampling was performed on days 1 and 29 of the first cycle </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Of the 37 patients entered, 18 patients &lt; or =12 years of age and 11 patients &gt;12 years of age were evaluable for toxicity </plain></SENT>
<SENT sid="6" pm="."><plain>In patients &gt;12 years of age, dose-limiting <z:hpo ids='HP_0002315'>headache</z:hpo> occurred in 2/2 patients at the 110 mg/m(2)/day dose level; 1/8 patients at 85 mg/m(2)/day developed dose-limiting <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In patients &lt; or =12 years of age, 3/5 patients at the starting dose level of 50 mg/m(2)/day developed dose-limiting <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e>; and 0/6 patients experienced dose-limiting toxicity at 35 mg/m(2)/day </plain></SENT>
<SENT sid="8" pm="."><plain>Reversible non-dose-limiting <z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">hepatotoxicity</z:e> was observed in 15 patients across <z:hpo ids='HP_0000001'>all</z:hpo> of the dose levels </plain></SENT>
<SENT sid="9" pm="."><plain>There was considerable interpatient variability in 9cRA plasma concentrations </plain></SENT>
<SENT sid="10" pm="."><plain>Peak plasma concentrations of 9cRA occurred at a median of 1.5 h after a p.o. dose, and the harmonic-mean terminal half-life was 43 min </plain></SENT>
<SENT sid="11" pm="."><plain>By day 29 of 9cRA administration, the plasma 9cRA area under the curve declined by an average of 65% from day 1 values </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: The dose-limiting toxicity of 9cRA in pediatric patients was neurotoxicity, primarily <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Younger children tolerate significantly lower doses of 9cRA than older children </plain></SENT>
<SENT sid="14" pm="."><plain>Similar to <z:hpo ids='HP_0000001'>all</z:hpo>-trans-<z:chebi fb="2" ids="26536">retinoic acid</z:chebi>, the pharmacokinetics of 9cRA demonstrated a wide degree of interpatient variability and decreased over time when administered on a daily basis </plain></SENT>
<SENT sid="15" pm="."><plain>The recommended Phase II dose of 9cRA in patients &lt; or =12 and &gt;12 years of age is 35 and 85 mg/m(2)/day, respectively </plain></SENT>
</text></document>